US Dollar vs Yen

ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。

ホーム
投資
株式
ヨーロッパ
EU
BioUv Group (ALTUV) 銘柄情報

BioUv Group (ALTUV)

1.365

0.00

(0.00%)

終了 6月14日 12:30AM

BioUv Group (ALTUV) 銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

1.365

( - )

買値

1.365

売値

1.38

出来高

4,354

1.365 日の範囲 1.38

1.216 52 週間の範囲 2.10

時価総額

前日終値

1.365

始値

1.37

時刻

最終取引時間

財務取引量

-

VWAP

-

平均取引量 (3 か月)

20,085 €

発行済株式数

13,588,258

配当利回り

PER

23.29

1 株当たり利益 (EPS)

0.06

歳入

36.87M

純利益

836.34k

BIO-UV Group S.A. designs, manufactures, and markets water treatment and disinfectant systems using ultraviolet, salt electrolysis, ozone, and advanced oxidation for individuals and professionals in France, rest of Europe, Asia, the Middle East, the Americas, and internationally. It operates through... BIO-UV Group S.A. designs, manufactures, and markets water treatment and disinfectant systems using ultraviolet, salt electrolysis, ozone, and advanced oxidation for individuals and professionals in France, rest of Europe, Asia, the Middle East, the Americas, and internationally. It operates through Products, Solutions, and After-Sales divisions. The company offers disinfection equipment and systems under the triogen, AKERON, 1001 Electrodes, and BIOSEA brands; spare parts; and commissioning services. It also provides maintenance services comprising inspection and diagnosis; cleaning and replacement of parts; calibration and adjustments; updates and upgrades; and training and technical support services. The company’s products are used in residential and commercial pools, aquariums, aquaculture, industrial water, municipal and domestic water, wastewater and reuse, and ballast water applications. It exports its products. BIO-UV Group S.A. was founded in 2000 and is headquartered in Lunel, France. 詳細を表示

セクター

Industrials

業界

Waste Management

ウェブサイト

www.bio-uv.com

本社

Lunel, France

設立

2026

BioUv Group is listed in the Industrials sector of the ユーロネクスト with ticker ALTUV. The last closing price for BioUv was 1.37 €. Over the last year, BioUv shares have traded in a share price range of 1.216 € to 2.10 €.

BioUv currently has 13,588,258 shares in issue. The market capitalisation of BioUv is 18.55 € million. BioUv has a price to earnings ratio (PE ratio) of 23.29.

表示するニュースはありません。

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-0.045	-3.1914893617	1.41	1.41	1.365	14758	1.38419901	DE
4	0.045	3.40909090909	1.32	1.44	1.32	19911	1.39646371	DE
12	-0.135	-9	1.5	1.516	1.216	19302	1.36624819	DE
26	-0.155	-10.1973684211	1.52	1.548	1.216	16986	1.37449657	DE
52	-0.72	-34.5323741007	2.085	2.1	1.216	15163	1.50939232	DE
156	-2.98	-68.584579977	4.345	4.5	1.216	17605	2.19874916	DE
260	-4.395	-76.3020833333	5.76	6.35	1.216	18025	3.409071	DE

ALTUV - Frequently Asked Questions (FAQ)

What is the current BioUv Group share price?

The current share price of BioUv Group is 1.365 €

How many BioUv Group shares are in issue?

BioUv Group has 13,588,258 shares in issue

What is the market cap of BioUv Group?

The market capitalisation of BioUv Group is EUR 18.55M

What is the 1 year trading range for BioUv Group share price?

BioUv Group has traded in the range of 1.216 € to 2.10 € during the past year

What is the PE ratio of BioUv Group?

The price to earnings ratio of BioUv Group is 23.29

What is the cash to sales ratio of BioUv Group?

The cash to sales ratio of BioUv Group is 0.52

What is the registered address of BioUv Group?

The registered address for BioUv Group is 850 avenue Louis Médard, Lunel, Languedoc-Roussillon, 34400

What is the BioUv Group website address?

The website address for BioUv Group is www.bio-uv.com

Which industry sector does BioUv Group operate in?

BioUv Group operates in the Waste Management sector

EZ2

11-12-22-24. 🙏

FlashySage44

FlashySage44 19分前

The day of reckoning is coming.
Two and a half weeks until the Next ER.
8 and a half until the August one.
No buyout in sight.
When will the longs start to question the buyout not happening?
I am very interested to see what this place will be saying come September

FlashySage44

FlashySage44 38分前

You’re not wolv?

jay_tee

jay_tee 54分前

That “yup still there” has to be the most asinine post ever. Where else would worthless paper/digital em shares be? Sure the shares are there BUT Seamus has taken its value and poured it into FOXO. He played us all well at least up to this point….safe shares sitting at .000001 is toilet paper

doogdilinger

doogdilinger 1時間前

Right place at the right time BERK buddy:

joe_techi

joe_techi 1時間前

The Rolling Stones - 2000 Light Years From Home
https://www.youtube.com/watch?v=RLhFT7YXnoI

xoom

xoom 1時間前

Exactly. Please ask your bosses to distribute shares asap..
Please ask your bosses to learn from Musk and how he treats his folks aka SpaceX shareholders.

Frankestin

Frankestin 1時間前

https://youtu.be/iH3oOVKt0WI?is=6VNcgxb-14JC0yZD

gregcod

gregcod 1時間前

Is july going to be IBATs Month?

rodeoup

rodeoup 2時間前

Spot on. This will be the best summer this company has ever had in my book!!!

Dragonman1

Dragonman1 2時間前

please send me the email

satter

satter 3時間前

Unless he is going to announce he is receiving some major investment, capital, nothing is going to change. Eric will just make it sound like some big change coming with his master of loaded words. And unfortunately once again you'll fall for it. Even after Eric mislead, misrepresented, again, how gr

US Market News

US Market News 3時間前

Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLLJune 14, 2026 3:15 AM
PR Newswire (US) BRUIN C

eagle8

eagle8 3時間前

Andrew Caravello, DO reposted
RJM
@rjmsoflo
The Day After Approval

Strategically Dangerous

$NWBO

What does NWBO look like to serious money the day after approval?

Because right now… the market sees OTC, delays, dilution

t1215s

t1215s 3時間前

Good morning people, There are. Others that could use that monies without a doubt for whatever their needs are , As for me ,I never really counted on it,hence my iffen on topic of returns , but I sure as heck would enjoying spending it and giving some away for sure ,as my life is just fine the way

Investor2014

Investor2014 4時間前

Terrie should go for $1249 and call it quits.

Tr8dervic

Tr8dervic 4時間前

I'm in with 5 11 24 19

Dave has 5 24 19 11

Waiting on Stephen

mrwrn2010

mrwrn2010 4時間前

“WHEREAS, Elite Laboratories, Inc., intends to amend ANDA No. 217939…”

I take that to mean they are just flipping to P3 and not starting from scratch. Question is how much review has the FDA done on this ANDA to date? And does the 30-month stay only affect final approval, or does it b

europa7

europa7 4時間前

Dell Technologies to Bring Grok SpaceXAI Models On-Premises to Enterprise Environments
"...Dell and SpaceXAI bring Grok AI models on-premises, giving enterprises advanced AI with complete data control and security..."
May 18, 2026
https://www.dell.com/en-us/blog/dell-technologie

Just give me $1.50

Just give me $1.50 4時間前

Does anybody know the answer to this question?

1. Does Elite have to submit a brand new Paragraph 3 filing for Generic OxyContin, meaning they'll have to wait the full 10 months for a Tentative Approval. Or can we just switch it from Paragraph 4 to Paragraph 3 with someone paperwor

Just give me $1.50

Just give me $1.50 5時間前

1. How do you know that isn't standard boilerplate language? In other words, every company in the same/similar situation does the exact same thing. Similar to 10-K's for publicly traded companies, literally every possible scenario and warning is listed in there.

2. What are the

barnstormer

barnstormer 5時間前

082, if she had ever said that there would be a record somewhere on file. You're good at making up supposed statements but as usual when pushed for support of your statement there isn't anything to be found. That's pretty par for the course with your act. Make up a story or accusation without suppor

British American Tobacco

NewDay Funding 2018-2

Hexagon Purus ASA

Perception Capital Corp IV

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。